AVLN (Avalyn Pharma) Total Operating Expense: $91.29 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AVLN Avalyn Pharma Inc AVLN
11 GF Score
Price $28.50
View Full Analysis

What is Avalyn Pharma Total Operating Expense?

Avalyn Pharma AVLN -1.01% 11 Total Operating Expense is $91.29 Mil as of Dec. 2025. GuruFocus rates AVLN with a GF Score™ of 11/100.

Avalyn Pharma's Total Operating Expense for the six months ended in Dec. 2025 was $91.29 Mil. Avalyn Pharma's Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was $91.29 Mil.

Avalyn Pharma Total Operating Expense Related Terms

Avalyn Pharma Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Avalyn Pharma's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avalyn Pharma Total Operating Expense Chart

Avalyn Pharma Annual Data
Trend Dec24 Dec25
Total Operating Expense
57.12 91.29

Avalyn Pharma Semi-Annual Data
Dec24 Dec25
Total Operating Expense 57.12 91.29
AVLN
11GF Score
Avalyn Pharma Inc AVLN
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avalyn Pharma Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


For stock reported annually, GuruFocus uses latest annual data as the TTM data. Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was $91.29 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $91.29 Mil mean?
Avalyn Pharma (AVLN) has a Total Operating Expense of $91.29 Mil as of Dec. 2025. Total operating expense is the primary recurring expense associated with central operations. View historical data on Avalyn Pharma and its competitors.
Is Avalyn Pharma's Total Operating Expense too high?
Avalyn Pharma's current Total Operating Expense is $91.29 Mil. Overall, Avalyn Pharma has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Avalyn Pharma's Total Operating Expense compare to TRAX and IMTX?
Avalyn Pharma's Total Operating Expense of $91.29 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Avalyn Pharma and its competitors. Avalyn Pharma's current Total Operating Expense is $91.29 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avalyn Pharma stock overvalued right now?
Avalyn Pharma (AVLN) has a current Total Operating Expense of $91.29 Mil. The current Total Operating Expense is $91.29 Mil. Avalyn Pharma's overall GF Score™ is 11/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Avalyn Pharma (AVLN), the current Total Operating Expense is $91.29 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Avalyn Pharma Business Description

Address 105 W First Street, Boston, MA, USA, 02127
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
11GF Score

Get the complete analysis for AVLN

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$28.50
Price